Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Atripla

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Atripla was produced by Gilead Sciences.

Gilead gets EU nod for TAF-based triple therapy for HIV

Gilead gets EU nod for TAF-based triple therapy for HIV

Atripla in 20016. ... Since then, Atripla has grown into a $3bn-plus product. "People living with HIV today are increasingly likely to be receiving treatment for other conditions - such as heart and liver disease -

ViiV and Janssen take long-acting HIV regimen into phase III

ViiV and Janssen take long-acting HIV regimen into phase III Gilead currently dominates the HIV treatment sector thanks to drugs like Truvada (emtricitabine and tenofovir disoproxil fumarate) and Atripla (favirenz/emtricitabine/tenofovir disoproxil fumarate), but ViiV is fighting back.

ViiV agrees $1.5bn deal to acquire BMS' HIV assets

ViiV agrees $1.5bn deal to acquire BMS' HIV assets cobicistat), Sustiva (efavirenz) and big-selling Atripla (efavirenz, emtricitabine, and tenofovir).

ViiV boosted by positive phase III results for HIV drug Triumeq

ViiV boosted by positive phase III results for HIV drug Triumeq The current HIV fixed-dose combination market leader is by Gilead's Atripla (tenofovir, emtrcitabine and efavirenz), which in 2013 achieved sales of $3.6bn.

BMS' HIV combination Evotaz cleared in Europe

BMS' HIV combination Evotaz cleared in Europe s Atripla and Stribild, Johnson &Johnson's Complera and ViiV Healthcare's Triumeq.

1 2 3 4 5 6 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics